Baird Starts CRISPR Therapeutics (CRSP) at Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500, Nasdaq set for higher open as oil prices extend declines, midterm results awaited
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- Goldman data shows hedge funds cut leverage at fastest pace since March
Tweet
Share
E-mailGet Alerts CRSP Hot Sheet
Price: $50.97 +1.96%
Rating Summary:
19 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 16 | New: 12
Rating Summary:
19 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 16 | New: 12
Join SI Premium – FREE
Baird analyst Jack Allen initiates coverage on CRISPR Therapeutics (NASDAQ: CRSP) with a Neutral rating and a price target of $46.00.
For an analyst ratings summary and ratings history on CRISPR Therapeutics click here. For more ratings news on CRISPR Therapeutics click here.
Shares of CRISPR Therapeutics closed at $50.84 yesterday.
You May Also Be Interested In
- CRISPR Therapeutics (CRSP) Reiterated at Market Outperform by Citizens on Robust CASGEVY Patient Pipeline
- CRISPR Therapeutics (CRSP) Misses Q3 EPS by 11c
- JPMorgan Starts TRex Bio (TRXB) at Overweight
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
